Call for proposals 2026 (HORIZON-HLTH-2026-04)
Ανοιχτή Πρόσκληση
Objectives
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
European countries and regions, along with international partners, are engaged in enhanced collaborative research efforts for the development of innovative personalised medicine approaches regarding prevention, diagnosis and treatment.
Healthcare authorities, policymakers and other stakeholders develop evidence-based strategies and policies for the uptake of personalised medicine in national or regional healthcare systems.
Health industries, policymakers and other stakeholders have access to efficient measures and investments to allow swift transfer of research and innovation into market.
Health industries and other stakeholders can accelerate the uptake of personalised medicine through the adoption of innovative business models.
Healthcare authorities, policymakers and other stakeholders use improved knowledge and understanding of the health and costs benefits of personalised medicine to optimise healthcare and make healthcare systems more sustainable.
Healthcare providers and professionals improve health outcomes, prevent diseases and maintain population health through the implementation of personalised medicine.
Stronger and highly connected local/regional ecosystems of stakeholders, including innovators, are in place and facilitate the uptake of successful innovations in personalised medicine, thus improving healthcare outcomes and strengthening European competitiveness.
Citizens, patients and healthcare professionals have a better knowledge of personalised medicine and are better involved in its implementation.
Stakeholders cooperate better and establish a network of national and regional knowledge hubs for personalised medicine.
Scope:
This topic targets an action under Article 24(2) HE Regulation aiming to add additional activities to existing grant agreements, together with additional partners that would deliver on those activities. The award of a grant to continue the partnership in accordance with this call should be based on a proposal submitted by the coordinator of the consortium funded under topic HORIZON-HLTH-2023-CARE-08-01: “European Partnership on Personalised Medicine” and the additional activities and additional partners to be funded by the grant should be subject to an evaluation. Taking into account that the present action is a continuation of the topic HORIZON-HLTH-2023-CARE-08-01: “European Partnership on Personalised Medicine” and foresees an amendment to an existing grant agreement, the proposal should present the additional activities (including additional partners) to be covered by the award primarily in terms of grant agreement revisions. Partners from countries recently associated to Horizon Europe from 2024 onwards (2024 included) are particularly welcome. The existing action, the “European Partnership for Personalised Medicine” (EP PerMed) can only reasonably be enhanced and enlarged on the basis of the existing consortium[1], as the co-funded framework established cannot simply be replaced without significant disruption, given the top-quality, long-term expertise and wide coverage of the beneficiaries comprising this consortium.
Ανοιχτή Πρόσκληση
Objectives
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
European countries and regions, along with international partners, are engaged in enhanced collaborative research efforts for the development of innovative personalised medicine approaches regarding prevention, diagnosis and treatment.
Healthcare authorities, policymakers and other stakeholders develop evidence-based strategies and policies for the uptake of personalised medicine in national or regional healthcare systems.
Health industries, policymakers and other stakeholders have access to efficient measures and investments to allow swift transfer of research and innovation into market.
Health industries and other stakeholders can accelerate the uptake of personalised medicine through the adoption of innovative business models.
Healthcare authorities, policymakers and other stakeholders use improved knowledge and understanding of the health and costs benefits of personalised medicine to optimise healthcare and make healthcare systems more sustainable.
Healthcare providers and professionals improve health outcomes, prevent diseases and maintain population health through the implementation of personalised medicine.
Stronger and highly connected local/regional ecosystems of stakeholders, including innovators, are in place and facilitate the uptake of successful innovations in personalised medicine, thus improving healthcare outcomes and strengthening European competitiveness.
Citizens, patients and healthcare professionals have a better knowledge of personalised medicine and are better involved in its implementation.
Stakeholders cooperate better and establish a network of national and regional knowledge hubs for personalised medicine.
Scope:
This topic targets an action under Article 24(2) HE Regulation aiming to add additional activities to existing grant agreements, together with additional partners that would deliver on those activities. The award of a grant to continue the partnership in accordance with this call should be based on a proposal submitted by the coordinator of the consortium funded under topic HORIZON-HLTH-2023-CARE-08-01: “European Partnership on Personalised Medicine” and the additional activities and additional partners to be funded by the grant should be subject to an evaluation. Taking into account that the present action is a continuation of the topic HORIZON-HLTH-2023-CARE-08-01: “European Partnership on Personalised Medicine” and foresees an amendment to an existing grant agreement, the proposal should present the additional activities (including additional partners) to be covered by the award primarily in terms of grant agreement revisions. Partners from countries recently associated to Horizon Europe from 2024 onwards (2024 included) are particularly welcome. The existing action, the “European Partnership for Personalised Medicine” (EP PerMed) can only reasonably be enhanced and enlarged on the basis of the existing consortium[1], as the co-funded framework established cannot simply be replaced without significant disruption, given the top-quality, long-term expertise and wide coverage of the beneficiaries comprising this consortium.